哌泊噻嗪合并治疗难治性精神分裂症的研究  

A study of clozapine combined with or without pipotiazine palmitate in refractory schizophrenia

作　　者：朱海兵[1] 余国汉[1] 邓德清[1] 朱玉华[1] 黎德美[1] 

机构地区：[1]广州市脑科医院精神科,510370

出　　处：《临床精神医学杂志》2002年第1期15-17,共3页Journal of Clinical Psychiatry

摘　　要：目的 :了解哌泊噻嗪与氯氮平治疗慢性难治性精神分裂症的疗效、副反应和血药浓度。　方法 :对 84例慢性难治性精神分裂症患者随机分为联合组和单用组 ,在治疗前、治疗后 1、2、3、6月进行简明精神病评定量表 (BPRS)和不良反应症状量表 (TESS)评定 ,并监测氯氮平血浓度。　结果 :总疗效联合组明显高于单用组。 BPRS总分和各因子分 (除焦虑抑郁分外 )在治疗后 2月即已有明显下降 ,两组副反应均较轻 ,氯氮平显效血浓度均高于 35 0μg/ L。　结论 :氯氮平合并哌泊噻嗪治疗慢性难治性精神分裂症具有较好疗效 ,副作用轻而少。Objective: To explore the efficacy and safety of pipotiazine palmitate and clozapine combination for the treatment of chronic refractory schizophrenia (CRS). Another aim is to assess the influence of pipotiazine palmitate on serum clozapine concentration. Method: 84 CRS patients were randomly assigned to two groups (clozapine with pipotiazine or clozapine alone) for 6 months. Serum clozapine concentrations were measured with HPLC,efficacy and side effects were assessed with the brief psychiatric rating scale (BPRS),treatment emergent symptom scale (TESS) before and after the treatment (1,2,3,6 month). Results:Clozapine combined with pipotiazine was superior to clozapine alone. Total BPRS and factors scores (except anxious-depression factor) decreased significantly more in clozapine-pipotiazine group than in clozapine group, but there was no significant difference in TESS. Blood clozapine concentration in patients with significant improvement were all higher than 350μg/L. Conclusion:Clozapine-pipotiazine is a highly effective and safe treatment for chronic refractory schizophrenia. Pipotiazine has little influence on serum clozapine concentration.

关 键 词：难治性精神分裂症 哌泊噻嗪 氯氮平 治疗 

分 类 号：R749.306[医药卫生—神经病学与精神病学] R971.4[医药卫生—临床医学]